InBio is looking forward to this year’s American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia! With its cobblestone streets, historic neighborhoods, and landmarks like Independence Hall and the Liberty Bell, Philadelphia blends rich American history with a vibrant modern culture, world-class museums, and an outstanding food scene.

InBio is delighted to announce that Martin Chapman, PhD, FAAAAI, President & CEO of InBio, is the recipient of the Jordan N. Fink Memorial Lectureship. This award will be presented prior to Martin’s plenary lecture on “Developing Precision Diagnostics and Therapeutics in Atopic Diseases”, this Saturday, Feb 28th at 8:15am EST in Level 2, Hall E.

Congratulations to Martin on this award, which is thoroughly deserved and represents peer recognition for Martin’s research over the past 40+ years. A globally recognized leader in allergen science and translational innovation, Martin has helped shape the field for decades. Please join us for his plenary lecture.

InBio scientists will be presenting several abstracts at AAAAI 2026. Most prominently, InBio and collaborators will present the allergenic structure of cat allergen, Fel d 1, as defined using human IgE monoclonal antibodies. We will be sharing the formulation of a synthetic ‘serum’ comprising of human IgE monoclonal antibodies to peanut allergens, together with recent data on the use of Apollo for detection of airborne microbes.

The AAAAI theme of Collaboration, Discovery and Innovation strongly aligns with InBio’s research strategy and our commitment to developing the molecular tools that enable next-generation diagnostics, immunotherapy, and environmental exposure assessment.

We hope you enjoy your time in Philadelphia. Come by and see us at Booth 608!

Beattie Sturgill

VP Business Development